WCN25-797 SAFETY AND EFFICACY OF IPTACOPAN IN PATIENTS WITH IgA NEPHROPATHY (IgAN) WITH BASELINE eGFR 20-<30 mL/MIN: PHASE 3 APPLAUSE-IgAN SUBCOHORT RESULTS
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-02-01
|
| Series: | Kidney International Reports |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2468024924023842 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849335878426558464 |
|---|---|
| author | Dmitrij Kollins Olympia Papachristofi Thomas Hach Severina Jacinto-Sanders Tobias Merkel Robert Schmouder Kenneth Kulmatycki Ronny Renfurm Vlado Perkovic |
| author_facet | Dmitrij Kollins Olympia Papachristofi Thomas Hach Severina Jacinto-Sanders Tobias Merkel Robert Schmouder Kenneth Kulmatycki Ronny Renfurm Vlado Perkovic |
| author_sort | Dmitrij Kollins |
| collection | DOAJ |
| format | Article |
| id | doaj-art-e7789fe1eb6c4fe59e8f123fcec53237 |
| institution | Kabale University |
| issn | 2468-0249 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Kidney International Reports |
| spelling | doaj-art-e7789fe1eb6c4fe59e8f123fcec532372025-08-20T03:45:08ZengElsevierKidney International Reports2468-02492025-02-01102S183S18410.1016/j.ekir.2024.11.362WCN25-797 SAFETY AND EFFICACY OF IPTACOPAN IN PATIENTS WITH IgA NEPHROPATHY (IgAN) WITH BASELINE eGFR 20-<30 mL/MIN: PHASE 3 APPLAUSE-IgAN SUBCOHORT RESULTSDmitrij Kollins0Olympia Papachristofi1Thomas Hach2Severina Jacinto-Sanders3Tobias Merkel4Robert Schmouder5Kenneth Kulmatycki6Ronny Renfurm7Vlado Perkovic8Cardio-Renal-Metabolic GDD, Novartis Pharma AG, Basel, SwitzerlandCardio-Renal-Metabolic GDD, Novartis Pharma AG, Basel, SwitzerlandCardio-Renal-Metabolic GDD, Novartis Pharma AG, Basel, SwitzerlandCardio-Renal-Metabolic GDD, Novartis Pharma AG, Basel, SwitzerlandCardio-Renal-Metabolic, Novartis Pharma AG, Basel, SwitzerlandCardio-Renal-Metabolic, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United StatesCardio-Renal-Metabolic, Novartis Institutes for Biomedical Research, Cambridge, MA, United StatesCardio-Renal-Metabolic, Novartis Pharma AG, Basel, SwitzerlandRenal and Metabolic Division, University of New South Wales, Sydney, Australiahttp://www.sciencedirect.com/science/article/pii/S2468024924023842 |
| spellingShingle | Dmitrij Kollins Olympia Papachristofi Thomas Hach Severina Jacinto-Sanders Tobias Merkel Robert Schmouder Kenneth Kulmatycki Ronny Renfurm Vlado Perkovic WCN25-797 SAFETY AND EFFICACY OF IPTACOPAN IN PATIENTS WITH IgA NEPHROPATHY (IgAN) WITH BASELINE eGFR 20-<30 mL/MIN: PHASE 3 APPLAUSE-IgAN SUBCOHORT RESULTS Kidney International Reports |
| title | WCN25-797 SAFETY AND EFFICACY OF IPTACOPAN IN PATIENTS WITH IgA NEPHROPATHY (IgAN) WITH BASELINE eGFR 20-<30 mL/MIN: PHASE 3 APPLAUSE-IgAN SUBCOHORT RESULTS |
| title_full | WCN25-797 SAFETY AND EFFICACY OF IPTACOPAN IN PATIENTS WITH IgA NEPHROPATHY (IgAN) WITH BASELINE eGFR 20-<30 mL/MIN: PHASE 3 APPLAUSE-IgAN SUBCOHORT RESULTS |
| title_fullStr | WCN25-797 SAFETY AND EFFICACY OF IPTACOPAN IN PATIENTS WITH IgA NEPHROPATHY (IgAN) WITH BASELINE eGFR 20-<30 mL/MIN: PHASE 3 APPLAUSE-IgAN SUBCOHORT RESULTS |
| title_full_unstemmed | WCN25-797 SAFETY AND EFFICACY OF IPTACOPAN IN PATIENTS WITH IgA NEPHROPATHY (IgAN) WITH BASELINE eGFR 20-<30 mL/MIN: PHASE 3 APPLAUSE-IgAN SUBCOHORT RESULTS |
| title_short | WCN25-797 SAFETY AND EFFICACY OF IPTACOPAN IN PATIENTS WITH IgA NEPHROPATHY (IgAN) WITH BASELINE eGFR 20-<30 mL/MIN: PHASE 3 APPLAUSE-IgAN SUBCOHORT RESULTS |
| title_sort | wcn25 797 safety and efficacy of iptacopan in patients with iga nephropathy igan with baseline egfr 20 30 ml min phase 3 applause igan subcohort results |
| url | http://www.sciencedirect.com/science/article/pii/S2468024924023842 |
| work_keys_str_mv | AT dmitrijkollins wcn25797safetyandefficacyofiptacopaninpatientswithiganephropathyiganwithbaselineegfr2030mlminphase3applauseigansubcohortresults AT olympiapapachristofi wcn25797safetyandefficacyofiptacopaninpatientswithiganephropathyiganwithbaselineegfr2030mlminphase3applauseigansubcohortresults AT thomashach wcn25797safetyandefficacyofiptacopaninpatientswithiganephropathyiganwithbaselineegfr2030mlminphase3applauseigansubcohortresults AT severinajacintosanders wcn25797safetyandefficacyofiptacopaninpatientswithiganephropathyiganwithbaselineegfr2030mlminphase3applauseigansubcohortresults AT tobiasmerkel wcn25797safetyandefficacyofiptacopaninpatientswithiganephropathyiganwithbaselineegfr2030mlminphase3applauseigansubcohortresults AT robertschmouder wcn25797safetyandefficacyofiptacopaninpatientswithiganephropathyiganwithbaselineegfr2030mlminphase3applauseigansubcohortresults AT kennethkulmatycki wcn25797safetyandefficacyofiptacopaninpatientswithiganephropathyiganwithbaselineegfr2030mlminphase3applauseigansubcohortresults AT ronnyrenfurm wcn25797safetyandefficacyofiptacopaninpatientswithiganephropathyiganwithbaselineegfr2030mlminphase3applauseigansubcohortresults AT vladoperkovic wcn25797safetyandefficacyofiptacopaninpatientswithiganephropathyiganwithbaselineegfr2030mlminphase3applauseigansubcohortresults |